Glucagon response to arginine after treatment of diabetes mellitus
- PMID: 1158041
- DOI: 10.2337/diab.24.9.811
Glucagon response to arginine after treatment of diabetes mellitus
Abstract
To investigate the aminogenic glucagon response in diabetes mellitus, arginine infusion tests were carried out on twenty-four diabetic patients before and after treatment. Eleven healthy men served as a control group. Plasma glucagon was measured by radioimmunoassay using an antiserum, G21, specific for pancreatic glucagon. Out of twenty-four patients, five were treated with diet alone, eight with sulfonylurea, and eleven with insulin. In all these diabetic groups, the glucose tolerance improved after treatment for diabetes mellitus, while the insulin response to the glucose did not show any remarkable change. The fasting levels of the plasma glucagon did not differ from that of the normal subjects both before and after treatment. Hyperresponsiveness of the plasma glucagon to arginine infusion was observed in all diabetic groups, in comparison with that of the normal controls. The exaggerated response of the plasma glucagon to arginine was lowered following appropriate treatment in each diabetic group. However, as far as the changes in glucagon area during the arginine test are concerned, the aminogenic hyperresponsiveness of the plasma glucagon was reduced prominently in the diabetic group treated with sulfonylurea. The relationship between the response of glucose and plasma insulin and between glucose and glucagon to arginine was investigated, and the importance of the changes in the insulin:glucagon ratio was emphasized. Moreover, the possibility that long-term administration of a sulfonylurea may reduce an exaggerated glucagon response to arginine was discussed.
Similar articles
-
Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic alpha cells.Diabetologia. 1991 Nov;34(11):801-6. doi: 10.1007/BF00408354. Diabetologia. 1991. PMID: 1769438
-
Alteration of plasma glucagon response to arginine after treatment in patients with diabetes mellitus, cushing's syndrome and hypothyroidism.Horm Metab Res. 1977 Jan;9(1):28-32. doi: 10.1055/s-0028-1093578. Horm Metab Res. 1977. PMID: 844789
-
Insulin and glucagon response in patients with chronic pancreatitis.Tohoku J Exp Med. 1976 Nov;120(3):287-98. doi: 10.1620/tjem.120.287. Tohoku J Exp Med. 1976. PMID: 996852
-
On the role of the gut in diabetic hyperglucagonaemia.Dan Med J. 2017 Apr;64(4):B5340. Dan Med J. 2017. PMID: 28385175 Review.
-
New horizons in our knowledge of diabetes mellitus.J Am Geriatr Soc. 1971 Nov;19(11):897-908. doi: 10.1111/j.1532-5415.1971.tb02205.x. J Am Geriatr Soc. 1971. PMID: 4949263 Review. No abstract available.
Cited by
-
Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?Curr Diab Rep. 2017 Oct 28;17(12):128. doi: 10.1007/s11892-017-0967-z. Curr Diab Rep. 2017. PMID: 29080075 Review.
-
The Impact of Amino Acids on Postprandial Glucose and Insulin Kinetics in Humans: A Quantitative Overview.Nutrients. 2020 Oct 21;12(10):3211. doi: 10.3390/nu12103211. Nutrients. 2020. PMID: 33096658 Free PMC article.
-
Effect of a long acting glucagon selective somatostatin analogue on plasma glucose, insulin and glucagon levels in the anaesthetized rat during arginine infusion.Diabetologia. 1979 Jul;17(1):59-64. doi: 10.1007/BF01222979. Diabetologia. 1979. PMID: 467854
-
Dose-kinetics of pancreatic glucagon responses to arginine and glucose in subjects with normal and impaired pancreatic B cell function.Diabetologia. 1981 Nov;21(5):452-9. doi: 10.1007/BF00257785. Diabetologia. 1981. PMID: 7028559 No abstract available.
-
Effect of glicentin-related peptides on glucagon secretion in anaesthetized dogs.Diabetologia. 1986 Jun;29(6):397-401. doi: 10.1007/BF00903352. Diabetologia. 1986. PMID: 3527839
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources